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Abstract
It is not known whether the addition of ezetimibe to statins adds cardiovascular protection beyond the expected changes in lipid
levels. Subjects with coronary heart disease were treated with four consecutive 1-week courses of therapy (T) and evaluations.
The courses were: T1, 100 mg aspirin alone; T2, 100 mg aspirin and 40 mg simvastatin/10 mg ezetimibe; T3, 40 mg
simvastatin/10 mg ezetimibe, and 75 mg clopidogrel (300 mg initial loading dose); T4, 75 mg clopidogrel alone. Platelet
aggregation was examined in whole blood. Endothelial microparticles (CD51), platelet microparticles (CD42/CD31), and
endothelial progenitor cells (CD34/CD133; CDKDR/CD133, or CD34/KDR) were quantified by flow cytometry. Endothelial
function was examined by flow-mediated dilation. Comparisons between therapies revealed differences in lipids (T2 and
T3,T1 and T4 for total cholesterol, LDL-C, and triglycerides; P,0.002 for all), as well as for endothelial function (T2.T1 and
T4, P=0.001). Decreased platelet aggregation was observed after aspirin (arachidonic acid, T1,T3 and T4, P=0.034) and
clopidogrel (adenosine, T3 and T4,T1 and T2, P,0.0001) therapy. Simvastatin/ezetimibe diphosphate did not change platelet
aggregation, the amount of circulating endothelial and platelet microparticles, or endothelial progenitor cells. Cardiovascular
protection following therapy with simvastatin/ezetimibe seems restricted to lipid changes and improvement of endothelial
function not affecting the release of microparticles, mobilization of endothelial progenitor cells or decreased platelet
aggregation.
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Introduction
Endothelial dysfunction has been associated with
decreased circulating endothelial progenitor cells (1,2)
and increased circulating endothelial microparticles (3,4).
Both conditions are influenced by classic risk factors (4-6)
and inflammatory status (7,8).
The pleiotropic effects of statin therapy include
increased nitric oxide bioavailability, antithrombotic, and
anti-inflammatory effects (9,10). However, the benefits of
vascular protection may vary according to the potency of
statin or pharmacokinetic interactions.
An increase in the number of circulating platelet
microparticles was reported in subjects with coronary heart
disease 1 week after rosuvastatin withdrawal, despite
continuing use of clopidogrel, suggesting that statins play a
role in antiplatelet activation (11). Furthermore, pharmaco-
kinetic interaction between clopidogrel and atorvastatin has
been described and related to the amount of circulating
platelet microparticles (12). Interactions between clopido-
grel and simvastatin may also be expected because they
are metabolized by the same hepatic microsomes (13,14).
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However, a decrease in the number of platelet and
endothelial microparticles has been seen after therapy
with simvastatin in diabetic and hypertensive subjects (15),
while in vitro studies have revealed increased release of
microparticles related to a simvastatin-mediated decrease
of protein prenylation (16). In addition, because ezetimibe
increases endogenous cholesterol synthesis (17), its
combination with simvastatin may perturb the effects of
the statin on microparticles when given alone.
Therefore, taking these interesting and controversial
aspects of vascular protection into account, this study was
designed to evaluate the effects of simvastatin/ezetimibe
therapy on microparticles, endothelial progenitor cells and
platelet aggregation in patients with stable coronary heart
disease.
Material and Methods
Participants were recruited from the cardiology out-
patient unit at Universidade Federal de Sa˜o Paulo. The
trial protocol was conducted in accordance with the ethics
standards of the institution and approval was obtained
from the local Ethics Committee. Patients were included
after having signed written informed consent. Eligible
subjects were those of both genders, 35-75 years of age,
and with stable coronary heart disease documented by
clinical symptoms and a previous coronary angiogram.
We excluded patients with planned revascularization and
those with comorbidities such as uncontrolled diabetes
(glycated hemoglobin .8.0%), liver (alanine aminotrans-
ferase .2.5 times the upper limit of normal) or renal
(creatinine .2.0 mg/dL) diseases, thyroid dysfunction
(thyroid-stimulating hormone .8 mU/mL), genetic hyperli-
pidemias, New York Heart Association class III/IV heart
failure, and those with any known intolerance or contra-
indication to the study drugs. Major characteristics of the
study population are shown on Table 1.
Subjects were instructed to discontinue statin therapy
for a week and to attend four consecutive study visits
according to the study protocol (Figure 1). Clinical
parameters and laboratory samples for biochemistry and
flow cytometry were obtained at each visit. Flow-mediated
dilation was evaluated with the application of four specific
therapies (T): T1, 100 mg aspirin alone; T2, 100 mg aspirin
and 40 mg simvastatin/10 mg ezetimibe; T3, 40 mg
simvastatin/10 mg ezetimibe and 75 mg clopidogrel
(300 mg on the first day); and T4, 75 mg clopidogrel alone.
The study drugs were Aspirina Prevent1 (Bayer, Brazil),
Vytorin1 (Merck, Brazil), and Plagrel1 (Sandoz, Brazil).
Laboratory assays
Blood samples were obtained after a 12-h fasting
period. Lipids were determined using automated assays
(Advia 2400, Siemens Healthcare Diagnostics, Japan)
and LDL cholesterol was estimated by the Friedewald
equation (18).
Measurements of endothelial progenitor cells (EPC)
were performed as previously reported (3,11,12). Briefly, the
cells were incubated for 30 min with fluorescently labeled
mouse anti-human antibodies: CD34 FITC (BD
Biosciences, USA), CD13 APC (Miltenyi Biotec, USA), and
Table 1. Baseline characteristics of the study population.
Characteristic Values
Age (years) 62 (57-70)
Gender
Male 13 (65%)
Female 7 (35%)
Medical history
Myocardial infarction 13 (65%)
Stable angina 11 (55%)
Percutaneous intervention 11 (55%)
Surgical revascularization 2 (10%)
Ischemic stroke 1 (5%)
Hypertension 18 (90%)
Diabetes 9 (45%)
Medications
Beta blocker 14 (70%)
Angiotensin-converting enzyme inhibitors 11 (55%)
Angiotensin receptor blockers 4 (20%)
Calcium channel blockers 6 (30%)
Diuretics 11 (55%)
Aspirin 20 (100%)
Nitrates 1 (5%)
Oral antidiabetic agents 9 (45%)
Insulin 1 (5%)
Data are reported as number with percent in parentheses or
median and interquartile range.
Figure 1. Study design. Therapy 1: 100 mg aspirin alone;
Therapy 2: 40 mg simvastatin/10 mg ezetimibe plus 100 mg
aspirin; Therapy 3: 300 mg clopidogrel (initial dose) followed
by 75 mg plus 40 mg simvastatin/10 mg ezetimibe; Therapy 4:
75 mg clopidogrel alone. Laboratory tests, including platelet
aggregation analyses, flow-mediated dilation, and quantification
of endothelial progenitor cells, platelet microparticles, and
endothelial microparticles were performed at the end of each
1-week (wk) therapy. All patients followed the consecutive
therapies without drug washout.
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KDR PE (R&D Systems, USA). Mouse antibody isotypes
were used as controls. A minimum of 500,000 events was
acquired for flow cytometry (FACSCalibur; BD Biosciences).
EPC counts are reported as the percentage of total
progenitor cells in the lymphocyte gate. For quantitation of
endothelial microparticles (EMPs) and platelet microparti-
cles (PMPs), blood samples were collected in citrated tubes
and centrifuged (160 g, 10 min) to obtain the platelet-rich
plasma (PRP). The PRP was then centrifuged (1500 g,
6 min) to obtain the platelet-poor plasma (PPP). The PPP
was incubated for 20 min with fluorescently labeled mouse
anti-human CD42 FITC and CD31 PE (BD Biosciences)
antibodies for PMP identification, and with CD51 FITC (BD
Biosciences) to detect EMP. Mouse antibody isotypes were
used as controls. We used disposable containers
(TruCOUNT Tubes; BD Biosciences) to determine the
number of microparticles per microliter of PPP.
Platelet aggregation was examined by multiple elec-
trode platelet aggregometry (Multiplate 5.0 Analyzer,
Diapharma, Germany) performed as previously reported
(11). Aggregation tests induced by collagen, thrombin
receptor-activating peptide 6, adenosine diphosphate,
and arachidonic acid were performed in duplicate.
Flow-mediated dilation (FMD) of the brachial artery
was assessed at each visit by ultrasound (Hewlett-
Packard SONOS 5500, USA) using a high-frequency
transducer, as previously reported (7,11). Briefly, patients
were required to fast and abstain from nitrates, alcohol,
and vasoactive medications for the previous 24 h. A
pneumatic cuff was placed on the extended left arm after a
20-min rest, when baseline images were acquired. The
cuff was inflated (.200 mmHg) to occlude blood flow for
5 min and images were acquired during the next 2 min
after cuff release. The greatest vasodilation was recorded.
Endothelium-independent responses following nitrates
were not performed because of the validity of FMD
measurements alone (19).
The effects of the four therapies on biochemistry,
platelet aggregation, flow-mediated dilation, and circulating
microparticles were tested using ANOVA-repeated mea-
sures followed by the Tukey test when appropriate. The
size of the study sample was based on a previous study of
our group with a similar design (11). Comparisons of the
percentages of circulating EPCs obtained with the thera-
pies were analyzed by the Wilcoxon test. Triglycerides
were log transformed. Tests were two-tailed and signifi-
cance was set at P,0.05.
Results
There were no adverse events during the study, drugs
were well tolerated, and complete adherence to the study
medications was observed in all visits for all patients.
Laboratory assay results were not affected by the study
treatments, except for lipids and platelet aggregation. Total
cholesterol and LDL cholesterol were reduced by 32 and
45%, respectively, after 1 week of simvastatin/ezetimibe
therapy; LDL cholesterol was ,100 mg/dL in 95% of
subjects and LDL cholesterol was ,70 mg/dL in 65% of
patients. A substantial rise in cholesterol was also observed
1 week after withdrawal of lipid-lowering therapy, corre-
sponding to a 41% increase in total cholesterol and an 83%
increase in LDL cholesterol. Significant changes of triglycer-
ides were also observed between visits (Table 2).
Antiplatelet tests showed decreases in aggregation in
response to arachidonic acid (P=0.034) and adenosine
diphosphate (P,0.0001) for patients treated with aspirin
and clopidogrel, respectively. When simvastatin/ezetimibe
Table 2. Effects of therapy on clinical parameters and biochemistry.
T1 T2 T3 T4
SBP (mmHg) 135 ± 3 130 ± 2 126 ± 3 126 ± 3
DBP (mmHg) 80 ± 2 78 ± 1 77 ± 2 78 ± 1
HR (bpm) 66 ± 2 68 ± 2 68 ± 2 66 ± 2
CK (U/L) 137 ± 16 138 ± 21 151 ± 26 140 ± 22
Creatinine (mg/dL) 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1
Glucose (mg/dL) 108 ± 8 116 ± 8 116 ± 7 107 ± 4
AST (U/L) 20 ± 2 22 ± 2 21 ± 2 19 ± 1
ALT (U/L) 22 ± 2 25 ± 3 27 ± 3 23 ± 3
TC (mg/dL) 185 ± 10 127 ± 7* 120 ± 7* 170 ± 9
HDL-C (mg/dL) 43 ± 2 44 ± 3 45 ± 3 45 ± 3
LDL-C (mg/dL) 110 ± 8 61 ± 6* 53 ± 6* 97 ± 7
Triglycerides (mg/dL) 156 ± 15 109 ± 7+ 98 ± 7+ 140 ± 14
Data are reported as means±SE. Therapy: T1: 100 mg aspirin; T2: 40 mg simvastatin/10 mg ezetimibe plus 100 mg aspirin; T3:
300 mg clopidogrel (initial dose) followed by 75 mg plus 40 mg simvastatin/10 mg ezetimibe; T4: 75 mg clopidogrel alone. SBP:
systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; CK: creatine kinase; AST: aspartate aminotransferase; ALT:
alanine aminotransferase; TC: total cholesterol; HDL-C and LDL-C: high- and low-density lipoprotein cholesterol, respectively.
* P,0.0001 TC and LDL-C on T2 and T3,T1 and T4; +P,0.002 triglycerides on T2 and T3,T1 and T4 (ANOVA-Tukey).
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therapy was given to patients taking aspirin or clopidogrel,
it did not modify the antiplatelet effects obtained when
these antiplatelet agents were given alone (Figure 2).
Systolic and diastolic blood pressure, as well as heart
rate, were unchanged throughout the study. FMD was
improved by simvastatin/ezetimibe therapy (P=0.001);
an increase of 249% in FMD was observed after 1 week
of therapy. Conversely, 1 week after simvastatin/
ezetimibe withdrawal, FMD returned to baseline values
(Table 3).
Endothelial and platelet microparticles were not
affected by any of the treatments, and the percentage of
circulating endothelial progenitor cells remained
unchanged throughout the study (Table 3).
Discussion
Patients with coronary heart disease should receive
an antiplatelet drug and are usually given lipid-lowering
therapy to achieve an LDL cholesterol of less than 70 mg/dL
Figure 2. Platelet aggregation in response to
therapies (T): T1: 100 mg aspirin; T2: 40 mg
simvastatin/10 mg ezetimibe plus 100 mg
aspirin; T3: 300 mg clopidogrel (initial dose)
followed by 75 mg plus 40 mg simvastatin/
10 mg ezetimibe; T4: 75 mg clopidogrel alone.
Decreased platelet aggregation was observed
after therapy with aspirin [arachidonic acid (ASP)
+T1,T3 and T4, P=0.034, ANOVA-Tukey] and
clopidogrel [adenosine diphosphate (ADP) *T3
and T4,T1 and T2, P,0.0001, ANOVA-Tukey].
Table 3. Effects of therapy on flow-mediated dilation, endothelial progenitor cells, endothelial and platelet microparticles.
Parameter T1 T2 T3 T4
FMD (%) 6.11 ± 1.86 15.28 ± 2.49* 12.48 ± 1.56 5.93± 1.35
EPC (% cells)
34/KDR 0.020 ± 0.005 0.010 ± 0.004 0.020 ± 0.004 0.010 ± 0.003
34/133 0.0511 ± 0.00718 0.0563 ± 0.01473 0.0432 ± 0.00662 0.0700 ± 0.01328
133/KDR 0.020 ± 0.011 0.010 ± 0.011 0.020 ± 0.008 0.030 ± 0.008
Microparticles (n/mL plasma)
EMP 1087 ± 336 1365 ± 403 1627 ± 364 1835 ± 917
PMP 32304 ± 5123 31139 ± 6422 33999 ± 4784 38705 ± 6395
Data are reported as means±SE. Therapy: T1: 100 mg aspirin; T2: 40 mg simvastatin/10 mg ezetimibe plus 100 mg aspirin; T3:
300 mg clopidogrel (initial dose) followed by 75 mg plus 40 mg simvastatin/10 mg ezetimibe; T4: 75 mg clopidogrel alone. FMD: flow-
mediated dilation; EPC: endothelial progenitor cells (CD34+/KDR+, CD34+/CD133+, and CD133+/KDR+); EMP: endothelial
microparticles (CD51+); PMP: platelet microparticles (CD42+/CD31+). * P=0.001 FMD on T2.T1 and T4 (ANOVA-Tukey).
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(20,21). This study showed that the LDL cholesterol
target could be achieved with sinvastatin/ezetimibe but
that these agents did not contribute to additional
antiplatelet effects beyond those already obtained by
clopidogrel or aspirin. Despite an early and pronounced
improvement on endothelial function with this lipid-
lowering regimen, no changes in the amount of micro-
particles or circulating endothelial progenitor cells were
seen. Taken together, the study showed that simvasta-
tin/ezetimibe therapy can be administered in combina-
tion with clopidogrel to patients with coronary heart
disease, but potential vascular benefits in addition to
lipid changes may not be seen.
Two recent meta-analyses of statin treatment clearly
showed the importance of a 2-3 mM reduction of LDL
cholesterol to obtain increased benefit in prevention of
major cardiovascular events (22,23). Although usually
safe, the use of high doses of statins may be accom-
panied by an increase in adverse muscle effects (24,25).
The effectiveness of simvastatin/ezetimibe to achieve
LDL cholesterol targets is well recognized, but some
pleiotropic effects of statins may not be fully expressed
when they are used together with other lipid lowering
strategies, (e.g., the combined use of ezetimibe and
simvastatin) (26). In this regard, our study shows that the
antiplatelet effect of aspirin or clopidogrel was unaffected
by the concomitant sinvastatin/ezetimibe therapy. In
addition, this lipid lowering therapy changed neither the
number of circulating microparticles nor the percentage of
endothelial progenitor cells. However, due to safety and
ethical reasons, the effect of simvastatin/ezetimibe alone
on platelet aggregation and microparticles, without anti-
platelet therapy, could not be assessed in this high-risk
patient group.
Simvastatin is a prodrug with the active metabolites
formed after biotransformation by the P450 cytochrome
(CYP) 3A4 system (27). Clopidogrel is metabolized in the
liver by several P450 cytochrome isoenzymes, including
CYP 3A4 to form its active thiol metabolite (28). A prior
study reported pharmacokinetic interactions between
statins and clopidogrel that decreased the antiplatelet
activity of clopidogrel (29). However, no compelling
evidence derived from clinical studies indicates the need
to avoid concomitant use of any specific statin with
clopidogrel (30). In fact, a recent study comparing
simvastatin 80 mg with simvastatin 10 mg plus ezetimibe
10 mg showed that FMD responses after treatment were
of similar magnitude and closely related to the changes in
LDL cholesterol (31). In our study, additional improvement
in FMD appeared to be associated with the low LDL
cholesterol levels that were achieved.
Our study tested the early effects of combined lipid
lowering therapy in subjects with stable coronary heart
disease and currently using antiplatelet therapies
because pharmacokinetic interactions between clopido-
grel and statins detected in previous studies affected
clopidogrel levels and the number of microparticles
released shortly after the start of statin therapy or its
withdrawal (11,12).
The large IMPROVE-IT trial (32) comparing ezetimibe/
simvastatin versus simvastatin monotherapy in patients
with acute coronary syndromes is ongoing and will
provide definitive data regarding long-term safety and
clinical benefits of combined lipid-lowering therapy in
subjects receiving antiplatelet therapy.
To summarize, our findings suggest that simvastatin/
ezetimibe use is an effective lipid-lowering therapy for
patients with stable coronary heart disease, including
concomitant use with clopidogrel. However, the potential
benefit of this lipid-lowering therapy for vascular protec-
tion seems restricted to its lipid-lowering properties and
improvement of endothelial function.
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